The enzyme telomerase is considered a potential marker for neoplastic tissue and is used as a diagnostic and prognostic tool in clinical medicine and therapeutics. For this reason, the possible role of telomerase activation in the process of malignant transformation is currently the subject of intense research efforts. The focus of the study reported here was to detect telomerase in 37 canine mammary samples, by comparing two methods: immunohistochemical (IHC) analysis for detecting the catalytic subunit of the enzyme, telomerase reverse transcriptase (TERT), and the telomeric repeat amplification protocol-enzymelinked immunosorbent assay (TRAP-ELISA), a polymerase chain reaction (PCR)-based technique that uses a colorimetric detection method. Using the TRAP-ELISA, samples were considered positive when they yielded a difference of at least 0.2 absorbance units between the readings at 450 nm versus 690 nm wavelength. On the basis of this criterion, 18 negative and 19 positive cases were obtained. Specific immunohistochemical staining was observed mainly in the nucleoli, to a lesser extent in the nuclei, and rarely in the cytoplasm of epithelial cells. A sample was considered positive when at least 10% of the epithelial cells had specific staining. The Pearson correlation between the TRAP-ELISA and IHC results was significant only when IHC nucleolar (r 5 0.53, P , 0.01) or nuclear (r 5 0.36, P , 0.05) staining or their combination (r 5 0.58, P , 0.01) was considered. Thus, IHC staining of nucleoli and nuclei can be considered as an alternative method to the TRAP-ELISA. The detection of telomerase in normal mammary gland and fibrocystic mastopathy using both methods does not support the idea that telomerase may be used as a specific marker of mammary neoplasia in dogs.
Introduction
Telomerase is an enzyme responsible for the maintenance of the extremities, the so-called telomeres, of all eukaryotic chromosomes. Telomeric DNA is formed by a number of repeated units corresponding to a repeated sequence (TTAGGG)n in mammals. 4 Telomeres represent structurally defined, specialized DNA-protein complexes that cap the ends of the linear chromosomes in the eukaryotic cells and are involved in several functions. They maintain chromosomal integrity, 4, 6, 7, 17, 30 influence the transcription of genes located near chromosome ends, 1 allow the double helix DNA placed at the end of the chromosomes to be completely replicated, 7, 21 and participate in meiotic chromosome segregation and in the organization of the nucleus. 11, 13, 14, 26 As a result of the inability of DNA polymerases to efficiently replicate the 59 ends of the linear chromosome, each round of cell division results in the loss of approximately 50 to 200 bp of the telomeric genome, a phenomenon known as the ''end replication problem.'' 1, 8, 22 This erosion leads to progressive telomeric attrition as cell division occurs, and shortening to a critical length is hypothesized to act as a trigger for cell growth arrest and cellular senescence. 1, 8, 22 The most important mechanism for maintaining telomere length is the activation of telomerase, a reverse transcriptase, the expression of which is strictly regulated. Telomerase consists of 2 essential components: one is the functional RNA component, which serves as a template for telomeric DNA synthesis; the other is a catalytic protein with reverse transcriptase activity. 1, 12, 17, 20, 38 Up regulation of the enzyme provides immortalizing capacity to neoplastic cells, allowing them to overcome telomeric instability, thus bypassing senescence and continuing to divide. 1, 15, 30, 41 Telomerase activation in tumors is considered the most important step in the so-called phenomenon of immortalization of neoplastic cells. A large number of studies have documented that most immortalized cells express telomerase, and one of the most exciting findings is the identification of telomerase activity in .90% of human cancers, whereas low or undetectable activity was found in most normal adult somatic tissues. 1, 13, 14, 47 For this reason, therapies that inhibit telomerase activity are currently thought to interfere with the growth of many types of neoplasia. 13 On the basis of the hypothesis that telomerase may represent a specific marker of neoplastic tissues, the development of methods to detect its activity may provide accurate, noninvasive diagnostic and prognostic tools. The telomeric repeat amplification protocol (TRAP), described by Kim et al. in 1994, 28 is the current gold standard technique for assessment of telomerase activity in tissue specimens. Although it is sensitive and specific, the TRAP assay is limited by the fact that it does not allow precise identification of the cells expressing the enzyme and is not applicable to formalin-fixed, paraffin-embedded tissues. In this respect, antibodies that can be used in immunohistochemical (IHC) analysis to detect the catalytic subunit (telomerase reverse transcriptase [TERT]) of the enzyme are now available; this method does not detect the functioning enzyme, but permits the definition of the specific expressing cell type and intracellular localization. The purpose of the study reported here was to compare 2 methods-IHC analysis and TRAP-ELISA, a variant of the original TRAP test-to detect telomerase activity in normal, hyperplastic, and neoplastic canine mammary tissue samples.
Materials and methods
Cases. The study population consisted of privately owned dogs that underwent mastectomy. A total of 37 canine mammary tissue samples (Table 1) , neoplastic and nonneoplastic, were obtained from the Obstetrics Unit of the Clinical Department of the Faculty of Veterinary Medicine of Bologna University, from referring veterinarians, or at necropsy from the Department of General Pathology and Pathological Anatomy of the same Faculty immediately after death of the dog. One sample of normal canine testis was used as a positive control for IHC analysis and the TRAP-ELISA.
Tissue sampling for the 2 techniques was carried out as follows: each fresh mammary nodule was divided into 0.5cm-thick blocks that were cut into 2 halves; one half was fixed in neutral-buffered 10% formalin, and the other half was flash frozen in liquid nitrogen and stored at 280uC until used for the molecular procedure. Two formalin-fixed and paraffin-embedded 4-mm-thick sections were stained with hematoxylin and eosin (HE) and TERT IHC methods. The HE-stained sections were used for diagnosis according to the WHO classification, as reported, 32 and for histologic stage assessment, following previously described criteria. 19 The histologic analysis was also a determinant in excluding those samples having scanty presence of neoplastic cells, or presenting necrotic areas or other components (hair follicles, skin, inflammatory cells) that would produce a telomerase-positive result, not strictly related to the characteristics of the tumor cells.
Immunohistochemical analyis for TERT. Four-micronthick sections were dewaxed in toluene and rehydrated. Endogenous peroxidase was blocked by immersion in 0.3% hydrogen peroxide for 30 min. The sections were then rinsed in Tris buffer (0.05 M Tris-aminomethane, 0.13 M NaCl) pH 7.6, immersed in citrate buffer (0.01 M citric acid monohydrate, pH 6.0), heated for two 5-min periods in a microwave oven at 750 W, and allowed to cool to room temperature (RT) for approximately 20 min. The primary antibody, antihuman TERT a (clone 44F12, diluted 1:50), was applied overnight at 4uC and was followed by use of a commercial streptavidin-biotin-peroxidase technique b with diaminobenzidine (DAB) as a chromogen (0.04% for 7 min). The sections were then counterstained with Papanicolau hematoxylin, rinsed in tap water, dehydrated, and mounted with DPX mountant. Negative controls were achieved by incubating the slides with a nonspecific antibody of the same isotype. Sections of normal testes and of canine heart were used as positive and negative controls, respectively.
The TRAP-ELISA. In this study, telomerase activity was detected by combining the polymerase chain reaction (PCR) assay and the ELISA by means of a commercially available kit c according to the manufacturer's protocol. Basically, the technique uses the telomerase enzyme present in the cell extract to add telomeric repeats TTAGGG to the 39 end of a biotin-labeled TS primer, which is recognized as a substrate. These telomerase { Histologic stage according to Gilbertson et al al. 19 : stage 0 5 noninfiltrating MT; stage 1 5 locally invasive MT; stage 2 5 invasive MT with intravascular emboli or regional lymph node involvement, or both. extended products are amplified by PCR analysis using specific primers. Digoxigenin-labeled probes complementary to the telomeric repeats are then added. The resulting products are immobilized via the biotin label to a streptavidin-coated microtitration plate. Immobilized amplicons are then detected by use of an antibody against digoxigenin that is conjugated to horseradish peroxidise. The products of the colorimetric reaction of peroxidase on the sensitive substrate (tetramethylbenzidine) are subsequently analyzed by the ELISA, which allows a semiquantitative assessment.
In the procedure, thin sections of frozen samples were made using a sterile surgical knife blade, collected in sterile disposable Petri dishes placed on dry ice, and immediately transferred to a sterile 1.5-ml microcentrifuge tube; 250 ml of ice-cold lysis reagent was added, and the sample was placed on ice for 30 min. The lysate was centrifuged at 16,000 3 g for 20 min at 4uC; the supernatant (about 175 ml of tissue extract) was carefully removed and transferred to a fresh tube. Protein concentration was determined using the Bradford protein assay. d Each PCR assay was carried out in a final volume of 50 ml with 1.5 mg of tissue extract in nuclease-free water and 25 ml of reaction mixture in a thermal cycler, e according to the following parameters: primer extension was carried out at 25uC for 30 min; 5 min at 94uC for telomerase inactivation, followed by a 33-cycle amplification (denaturation: 94uC for 30 sec; annealing: 50uC for 30 sec; elongation: 90 sec at 72uC) and 10 min at 72uC were required for final elongation.
Five microliters of amplified products was mixed with 10 ml of denaturation reagent and incubated at RT for 10 minutes. One hundred microliters of hybridization buffer T was then added and mixed thoroughly; 100 ml of mixture/sample was distributed into a well of a microtitration plate (MTP modules) and incubated at 37uC on a shaker (350 rpm) for 2 hours. One hundred microliters of 10 mU of an antidigoxigenin antibody/horseradish peroxidise-conjugated working solution/ml was added to the well, which then was incubated for another 30 min at RT with shaking. The solution was removed completely, and the precipitate was rinsed 5 times with 250 ml of 13 wash buffer/well for at least 30 sec. After removing the buffer, 100 ml of tetramethylbenzidine (TMB) substrate solution/ well, prewarmed at RT, was added and incubated for color development at RT for 15 min while the plate was rotating. At the end, without removing the reacted substrate, 100 ml of stop reagent was added to stop color development. Using a microplate reader, the absorbance of the sample was measured immediately at a wavelength of 450 nm with a reference wavelength of 690 nm (blank). The results were reported as difference in absorbance, DA 5 A 450 nm 2 A 690 nm . For negative controls, values routinely found are ,0.05 DA units. Apart from the testis, an additional positive control was added and was chosen among the tumor samples because it displayed a positivity (DA varied from 0.7 to 0.8 DA units), even higher than the value for the testis.
The TERT immunohistochemical analysis and TRAP-ELISA scores and correlation. Using the TRAP-ELISA, samples were considered as telomerase positive if DA was higher than 0.2 DA units, whereas using IHC analysis, a score of 10% was considered discriminant between negative (,10%) and positive (.10%) cases. Correlation between anti-TERT IHC analysis and the TRAP-ELISA was tested by the Pearson method. A value of P , 0.05 was considered significant.
Results
Mean age of the bitches enrolled in the study was 10.07 years, which was similar to the age of dogs used in previous studies. 9, 16, 33 The samples were divided into 4 histopathologic groups: normal mammary glands (3 cases), fibrocystic mastopathies (3 cases), benign tumors (17 cases), and malignant tumors (14 cases). Immunohistochemical expression by anti-TERT monoclonal antibody, presented 3 patterns of staining: nucleolar (the most frequent; Fig. 1A, 1B ; Fig. 2 ), diffuse nuclear (Fig. 1C, 1D, 1E ), and cytoplasmic (rare; Fig. 1E ). The testis had a nucleolar reaction and, rarely, a diffuse nuclear stain (Fig. 1C) .
The normal resting mammary gland had nucleolar staining in 5 to 10% of the ductal cells, whereas the stroma did not stain. In the hyperplastic mammary gland, the epithelium of the ducts had strong nucleolar staining, weaker diffuse nuclear staining, and rare cytoplasmic expression, involving 25 to 100% of the ductal and the secreting cells; myoepithelial cells had rare nucleolar staining, and again, the stroma remained unstained. The cysts, in the case of fibrocystic mastopathy, reflected the expression of the normal gland in the resting state, whereas for atypical ductal hyperplasia, the pattern was the same as that seen for the hyperplastic normal mammary gland. Benign tumors had variable staining, mainly nucleolar and, to a lesser extent, nuclear, ranging from 5 to 80% of the epithelial cells (rare in myoepithelial cells). Occasionally, the stroma had nucleolar expression. The cartilaginous and bone metaplasia observed in mixed tumors was always unstained. 18 The pattern of expression of malignant tumors overlapped that of benign conditions, but stromal ( Fig. 1E ) and cytoplasmic staining (Fig. 1B) were stronger, especially in the invasive component and, in particular, in the intravascular emboli and in many infiltrating lymphocytes (Fig. 1D ). The cut-off level between positive and negative samples by IHC analysis was considered to be 10% positive cells. Using this criterion, 18 cases and the testis were considered positive (1 normal mammary gland, 2 fibrocystic mastopathies, 7 benign tumors, and 8 malignant tumors) and 19 were negative (2 normal mammary glands, 1 fibrocystic mastopathy, 10 benign tumors, and 6 malignant tumors). Using the TRAP-ELISA, 19 mammary samples and a testis were positive (2 normal mammary glands, 1 fibrocystic mastopathy, 8 benign tumors, and 8 malignant tumors) and 18 were negative (1 normal mammary gland, 2 fibrocystic mastopathies, 9 benign tumors, and 6 malignant tumors). When the results obtained by IHC analysis and TRAP-ELISA were compared, the Pearson correlation was significant only when IHC nucleolar or nuclear staining was compared with TRAP-ELISA results ( Table 2 ). The higher correlation was obtained when nuclear and nucleolar expression were considered together. Considering this combination of the staining, 30 samples were concordant, (79%: 14 both negative and 16 both positive) and 8 were discordant (4 TRAP-ELISA+/ IHC2 and 4 TRAP-ELISA2/IHC+); the percentage of agreement between TRAP-ELISA and TERT IHC was 71.4% in malignant and 88.2% in benign tumors, whereas it was lower (66.6%) in fibrocystic mastopathy and in normal mammary glands (Table 3 ).
Discussion
In this study, IHC analysis and the TRAP-ELISA were used to detect telomerase in normal, hyperplastic, and neoplastic canine mammary tissue. The reactivity of the anti-TERT antibody with canine samples and the application of the TRAP-ELISA in the veterinary field are innovative.
The main aim of this study was to compare IHC analysis and the TRAP-ELISA for assessment of telomerase activity in canine mammary tissue. The 2 techniques provide different results, which need to be interpreted; although IHC analysis determines the presence of the catalytic subunit of telomerase (on which the enzymatic activity depends, thus providing an indirect method for detecting the presence of the enzyme), TRAP-ELISA estimates the amount of active telomerase. The ultimate goal was to validate the use of IHC analysis, which is less expensive and, unlike the TRAP-ELISA, allows the testing of archival material as well. Similar studies have already been conducted in human medicine, 24, 27, 31, 38, 50 with the results showing good correlation between the 2 techniques.
The immunolocalization of TERT in cancer specimens is strictly related to the level of telomerase activity. In a recent study, 24 it was observed that, in cancers with high telomerase activity assayed by TRAP, TERT expression was detected in almost all neoplastic cells; on the contrary, tumors with low telomerase activity had fewer TERT-positive cancer cells. With regard to IHC expression of human TERT, variable results are reported in literature: IHC staining was either confined to the nucleus, 24 present in the nucleus and nucleolus, 42 or in the cytoplasm. 46 This variability may reflect the use of antibodies against different epitopes of the enzymatic component. In this study, IHC analysis by use of anti-TERT revealed localization of the stain similar to that reported in human literature, but only IHC nucleolar and nuclear stains correlated with the results of the TRAP-ELISA, allowing the former to be considered an alternative method to the latter. It should be noted that the various patterns of IHC reactivity were not always present simultaneously within a cell, indicating that the 3 immunolocalizations can be seen as different moments of the intracellular processing of TERT protein.
Immunohisotchemical analysis and the TRAP-ELISA produced some discrepancies. Negative TRAP-ELISA results from samples with positive IHC results might be attributable to sample variability, the presence of inhibitors of Taq polymerase in the protein extract, extreme weakness of the RNA component of telomerase (responsible for the elongation of the synthetic primer used in the biomolecular approach for testing the presence of enzymatic activity), or protein degradation during sample collection or processing. Regarding sample variability, it was observed that IHC staining was not always uniformly distributed throughout the tissue section, as hot spots of reactivity were often observed; thus, it is possible that different areas with variable amounts of enzyme activity could have been sampled for the TRAP-ELISA even if a rigorous protocol of sampling was followed, as reported in the Materials and methods section. The presence of Taq polymerase inhibitors causing negative TRAP-ELISA results in tissues revealed positive by IHC analysis has already been reported for human cancers. 29, 49 The results of the study reported here also indicated the possible presence of Taq polymerase inhibitors within canine mammary gland tumors. Indeed, it was often observed that, as protein extracts were diluted, the absorbance of the amplification products increased. The TRAP-ELISA+/IHC2cases might be explained by the fact that prolonged formalin fixation could have denatured some epitopes with which the antibodies react.
One of the first TERT versus TRAP comparative studies was conducted in human medicine 24 on several tissues, neoplastic and normal, such as lung, breast, stomach, liver, pancreas, and colon. Subsequently, a similar investigation 50 tested breast tumors. However, neither of those studies investigated the correlation between the 2 techniques. In the present study, a good level of agreement was found between the TRAP-ELISA and IHC analysis of malignant (71.4%) and benign (88.2%) tumors.
Several studies have described the relationship between enzyme activity and malignancy of the tumor but, at present, interpretation of the results of such studies remains controversial. 39, 43 Various studies of human breast cancer focused on the importance of this enzyme as a diagnostic marker for malignant behavior because the enzyme activity was reported to be correlated to tumor malignancy, 36, 44, 49 high-stage malignant compared with low-stage, 3, 23 in those cases with lymphatic or lymph node invasion, or both, in comparison with those without such an involvement. 34, 37 The general idea is that telomerase should not be considered an absolute marker of malignancy; this is because its activity has been found in benign tumors as well, even though high-grade malignant tumors are more often detected with higher levels of expression. Similar conclusions can be drawn for animal tumors as well. A strong correlation between telomerase expression and malignancy has been reported in veterinary medicine. 4, 51, 52 In dogs, a large number of tumor types have been studied using the TRAP assay. 4, 35 The correlation between telomerase activity and histopathologic diagnosis was significant; malignant tumors were usually positive for telomerase activity whereas benign and normal tissues were negative. On the other hand, various authors have also observed that the reactivation of telomerase may be associated with benign and malignant tumors in canine mammary gland tumors, irrespective of the histologic classifications (diagnosis and grade). 51 A study of canine mammary samples conducted by the same authors 2 years later indicated that telomerase activity was detectable in all of the adenomas, benign mixed tumors, and adenocarcinomas examined. In Table 3 . Concordance between TRAP-ELISA and antitelomerase reverse transcriptase-immunohistochemical (TERT-IHC) results in all cases (A; 79.0%), and in malignant (B; 71.4%), and benign (C; 88.2%) tumors. In NMG and FCM, the concordance was 66.6% (NMG: 1 negative case and 1 positive case using both tests; 1 TRAP-ELISA-positive/TERT-IHC-negative case; FCM: 1 negative case and 1 positive case for both tests; 1 TRAP-ELISAnegative/TERT-IHC-positive case). TERT-IHC  TERT-IHC  +  +  +  2  2  2  TTRAP-ELISA  TTRAP-ELISA  TTRAP-ELISA  +  +  +  16  6  7  4  2  1  2  2  2  4  2  1  14  4  8  A  B  C contrast, all normal mammary glands, hyperplasias, and malignant mixed tumors were negative for telomerase activity. 52 Moreover, the data obtained in the study reported here do not support the prediction that a strict association exists between telomerase expression and neoplasia; normal as well as neoplastic tissues yielded positive results using the TRAP-ELISA and IHC analysis. Therefore, although telomerase analysis may be useful in veterinary medicine as a diagnostic and prognostic tool for animals with mammary tumors, it should only be considered as a further confirmatory test after routine histologic analysis or as a complementary test.
TERT-IHC
Although .90% of human and animal tumors are positive for telomerase activity, 51 some normal somatic tissues with a high renewal rate (bone marrow, activated lymphocytes, basal skin cells, hair follicles, gastrointestinal tract mucosa, and endometrium) 2, 10, 25, 40, 45, 48, 53 have been found to have low telomerase activity. On the basis of these results, telomerase should not be considered a sure indicator of tumors. In this study, positive telomerase activity was observed in normal mammary glands, atypical ductal hyperplasia, and benign and malignant tumors (Table 3 ). Therefore, telomerase may not represent a specific marker in canine neoplastic tissues. However, preliminary screening may allow selection of cases that express high levels of the enzyme and can, thus, be candidates for therapy with antitelomerase agents.
